logo

For the Inventor, By the Inventor

Wilmington, DE, United States of America

John Francis McElroy

This inventor holds 33 USPTO granted patents and 4 published patent applications, primarily in Cannabinoid Research. Top assignees: Jenrin Discovery, Inc., Bristol-Myers Squibb Pharma Company, Dupont Pharmaceuticals Company. Active years: 1994-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Francis McElroy. Retrieved from https://idiyas.com/inventor/john-francis-mcelroy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 

% Patents Active = 54.5

Average Co-Inventor Count = 2.1

ph-index = 8

Forward Citations = 189(Granted Patents)


Location History:

  • Alhambra, CA (US) (1994)
  • Wilmington, DE (US) (2001 - 2021)

Company Filing History:

goldMedal27 out of 27 
 
Jenrin Discovery, Inc.
 patents
silverMedal1 out of 234 
 
Bristol-Myers Squibb Pharma Company
 patents
bronzeMedal1 out of 106 
 
Dupont Pharmaceuticals Company
 patents
4. 1 out of 1 
 
Jenrm Discovery, Inc.
 patent
5. 1 out of 1 
 
Jensen Discovery, Inc.
 patent
6. 1 out of 107 
 
Wisys Technology Foundation, Inc.
 patents
7. 1 out of 834,570 
Other
 patents

Years Active: 1994-2021

Loading Chart...
Areas of Expertise:
Cannabinoid Receptor Antagonists
Inverse Agonists
Metabolic Disorders
Obesity Treatments
MAO-B Inhibitors
Anti-Malarial Agents
5-HT7 Receptor Antagonists
Pharmaceutical Compounds
Disease Conditions
Cancer Treatment
Purinergic Compounds
Anxiolytic Agents
33 patents (USPTO):Explore Patents
1. 11179370 - Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers (2021-11-23),
2. 10617673 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes (2020-04-14),
3. 9987253 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes (2018-06-05),
4. 9517228 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes (2016-12-13),
5. 9133127 - Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers (2015-09-15),
6. 8853252 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes (2014-10-07),
7. 8716265 - 4-quinolinemethanols as anti-malarial agents (2014-05-06),
8. 8680131 - Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers (2014-03-25),
9. 8648072 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes (2014-02-11),
10. 8580768 - Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes (2013-11-12),
11. 8541475 - MAO-B inhibitors useful for treating obesity (2013-09-24),
12. 8334282 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes (2012-12-18),
13. 8252791 - Purine compounds as cannabinoid receptor blockers (2012-08-28),
14. 8236821 - Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity (2012-08-07),
15. 8217038 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes (2012-07-10),

Title: John Francis McElroy: Innovator in Cannabinoid Research

Introduction

John Francis McElroy, residing in Wilmington, DE, is a notable inventor with a remarkable portfolio of 32 patents. His contributions to the field of cannabinoid research have positioned him as a key player in developing innovative therapeutic solutions.

Latest Patents

Among his latest groundbreaking patents are "Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers." This invention introduces novel, diastereomeric pyrazolines that function as cannabinoid receptor blockers, providing pharmaceutical compositions and methods for treating various health conditions, such as obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and cancers. Additionally, he has patented similar applications focused specifically on metabolic disorders, reaffirming his dedication to addressing significant health challenges.

Career Highlights

Throughout his career, John has held influential positions at various esteemed organizations. Notably, he has worked at Jenrin Discovery, Inc., and Wisys Technology Foundation, Inc., where he contributed to advancing research and development in cannabinoid applications.

Collaborations

In his journey, John has collaborated with distinguished peers, including Robert J Chorvat and Rajagopalan Parthasarathi. These partnerships have enhanced his research efforts and expanded the impact of his inventions.

Conclusion

John Francis McElroy's work exemplifies the innovative spirit inherent in modern scientific research. His extensive roster of patents underscores his commitment to finding solutions for serious medical conditions, particularly in the realm of cannabinoid therapies. Through his ongoing contributions, McElroy continues to shape the future of health-related innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…